AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.
| Revenue (Most Recent Fiscal Year) | $75.13M |
| Net Income (Most Recent Fiscal Year) | $-146.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 53.04 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.18 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -251.73% |
| Net Margin (Trailing 12 Months) | -218.54% |
| Return on Equity (Trailing 12 Months) | -15.35% |
| Return on Assets (Trailing 12 Months) | -10.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.48 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 326.62M |
| Free Float | 233.86M |
| Market Capitalization | $3.60B |
| Average Volume (Last 20 Days) | 3.07M |
| Beta (Past 60 Months) | 1.59 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 28.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |